Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mei Pharma Inc (NQ: MEIP ) 3.550 +0.030 (+0.85%) Streaming Delayed Price Updated: 9:58 AM EDT, Jul 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mei Pharma Inc < Previous 1 2 3 4 5 6 7 Next > Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session July 22, 2024 Via Benzinga MEI Pharma to Consider Strategic Alternatives July 22, 2024 From MEI Pharma, Inc. Via Business Wire 7 Undervalued Biotech Stocks to Buy for Big-Time Returns July 01, 2024 The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. Via InvestorPlace Earnings Outlook For MEI Pharma September 25, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session May 16, 2024 Via Benzinga Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) May 14, 2024 From Glancy Prongay & Murray LLP Via Business Wire MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024 May 09, 2024 MEIP stock results show that MEI Pharma beat analyst estimates for earnings per share the third quarter of 2024. Via InvestorPlace MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights May 09, 2024 From MEI Pharma, Inc. Via Business Wire MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients April 11, 2024 From MEI Pharma, Inc. Via Business Wire MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum April 10, 2024 From MEI Pharma, Inc. Via Business Wire MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia March 26, 2024 From MEI Pharma, Inc. Via Business Wire 5 Value Stocks In The Healthcare Sector February 19, 2024 Via Benzinga Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) February 15, 2024 From Glancy Prongay & Murray LLP Via Business Wire MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights February 13, 2024 From MEI Pharma, Inc. Via Business Wire MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024 January 16, 2024 From MEI Pharma, Inc. Via Business Wire A Look Into Healthcare Sector Value Stocks January 08, 2024 Via Benzinga Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) December 14, 2023 From Glancy Prongay & Murray LLP Via Business Wire MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023 December 11, 2023 From MEI Pharma, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Intraday Session November 16, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session November 16, 2023 Via Benzinga MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights November 09, 2023 From MEI Pharma, Inc. Via Business Wire MEI Pharma to Present at the Stifel 2023 Healthcare Conference November 08, 2023 From MEI Pharma, Inc. Via Business Wire MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock November 06, 2023 From MEI Pharma, Inc. Via Business Wire MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023 November 02, 2023 From MEI Pharma, Inc. Via Business Wire MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital November 01, 2023 From MEI Pharma, Inc. Via Business Wire MEI Pharma Recommends Stockholders Not to Consent October 17, 2023 From MEI Pharma Via Business Wire MEI Pharma Adopts Limited-Duration Stockholder Rights Plan October 02, 2023 From MEI Pharma, Inc. Via Business Wire MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions September 28, 2023 From MEI Pharma, Inc. Via Business Wire MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights September 26, 2023 From MEI Pharma, Inc. Via Business Wire Earnings Scheduled For September 26, 2023 September 26, 2023 Companies Reporting Before The Bell • Ferguson (NYSE:FERG) is estimated to report quarterly earnings at $2.46 per share on revenue of $7.60 billion. Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
